Agenus Inc

Research Agenus Inc (AGEN) on Bullrun: valuation model: 290.1% undervalued, market cap USD 131.17M, P/E 1.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAGEN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal290.1% undervalued
• Market capUSD 131.17M
• P/E1.9
• Financial periodFY2025
• RevenueUSD 114.20M
• Revenue growth10.4%
• Net income-USD 3.08M
• Free cash flow-USD 77.20M
• Gross margin99.1%

Valuation Snapshot

Bullrun's latest valuation model marks Agenus Inc as 290.1% undervalued; latest market cap is USD 131.17M; P/E is 1.9.

About Agenus Inc

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody;

Frequently asked questions

Is Agenus Inc overvalued or undervalued?

Bullrun's valuation model currently marks Agenus Inc as 290.1% undervalued.

What is Agenus Inc's market cap?

Agenus Inc's market capitalization is USD 131.17M.

What is Agenus Inc's P/E ratio?

Agenus Inc's price-to-earnings (P/E) ratio is 1.9.

What does Agenus Inc do?

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.